Covidien agreed to sell its 37 U.S. radiopharmacies to Triad Isotopes for an undisclosed amount.
Covidien (NYSE:COV) agreed to sell its 37 radiopharmacies in the U.S. to Triad Isotopes Inc. of Orlando, Fla., for an undisclosed amount.
The Mansfield, Mass.-based medical products conglomerate said it's making the move after examining the proverbial "strategic alternatives" to focus on businesses with more growth potential. Covidien has 38 of the businesses worldwide, including one in London and the 37 in the U.S., under its Mallinckrodt brand.
The company said the U.S. radiopharmacies pulled in $180 million in net sales during fiscal 2009.
Hologic wins FDA approval for its new C-View 2D imaging software for use with its 3D breast...
The hallowed emerging markets in Brazil, Russia, India and China aren't generating the kind of growth...
Medical device company Bausch + Lomb won FDA approval for its Trulign Toric intraocular lens, the 1st...
California medical device maker Claret Medical's embolic protection technology captures debris...
Texas-based Galt Medical Corp. is reportedly laying off 139 workers as it shutters its hometown plant...